Biotech and Pharmaceuticals Life Sciences

More

  • Roche earnings miss forecasts

    Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.

  • Health tech: UK vs USA

    The U.K. is becoming a test bed for developing and proving new digital technologies in health care says George Freeman MP, UK minister for life sciences, as he discusses health tech trends.

  • 2016 will be pivotal to health care: JP Morgan

    Cathrin Petty, head of EMEA healthcare at JP Morgan, says 2016 will be a pivotal year for the health care industry due to new product launches and approvals, as well as commercial headwinds.

  • Jan 25- GlaxoSmithKline Plc is concluding feasibility studies evaluating whether its vaccine technology is suitable for the Zika virus, which has been linked to brain damage in thousands of babies in Brazil, a spokeswoman told Reuters. Zika will likely spread to all countries in the Americas except for Canada and Chile, the World Health Organization said on...

  • BOSTON, Jan 25- Zafgen's stock tumbled as much as 11.5 percent on Monday after hedge fund Kerrisdale Capital said it has a short bet on the biopharmaceutical company's stock, arguing that U.S. regulators will not approve the sale of its obesity drug. "Zafgen's deadly obesity drug has no reasonable chance of FDA approval," the hedge fund wrote in an 11- page report...

  • BOSTON, Jan 25- Biopharmaceutical company Zafgen's stock tumbled as much as 11.5 percent in early trading on Monday after hedge fund Kerrisdale Capital said it has a short bet on the stock, arguing that U.S. regulators will not approve the sale of its obesity drug. "Zafgen's deadly obesity drug has no reasonable chance of FDA approval," the hedge fund wrote in an 11-...

  • NEW YORK, Jan 22- The U.S. Federal Trade Commission is investigating Turing Pharmaceuticals for possible antitrust violations in connection with the company's decision to hike the price of a life-saving drug by more than 5,000 percent, a lawyer for former Chief Executive Officer Martin Shkreli wrote on Friday. The probe was disclosed in a letter to the U.S....

  • NEW YORK, Jan 21- Former pharmaceutical executive Martin Shkreli was on a collision course with Congress on Thursday as lawmakers warned he could be prosecuted for contempt if he does not appear next week for a hearing about drug prices. A lawyer for Shkreli informed the U.S. House Committee on Oversight and Government Reform of his intent not to answer...

  • The sun is shining on our sector: CEO

    Karl-Ludwig Kley, chairman and CEO of Merck, is positive about the prospects for the health care and life sciences sector.

  • DAVOS/ LONDON, Jan 20- The Gavi global alliance for vaccines and immunisation group signed a $5 million advance purchase commitment on Wednesday to buy a vaccine being developed by Merck to protect against future outbreaks of the deadly Ebola virus. Gavi said the agreement would help the U.S. drugmaker take the experimental Ebola vaccine through late-stage...

  • We are prepared for the future: DSM CEO

    Feike Sijbesma, CEO of DSM, says the industry is changing the world transitions from fossil fuels to bio-renewable energy and discusses the economy in Europe and China.

  • Funds who placed a broad array of bets produced some of the strongest gains, beating star managers like Bill Ackman, David Einhorn and Larry Robbins who invested more narrowly and ended 2015 with steep losses. Funds to produce double-digit returns in 2015 include Citadel, Millennium Management, Visium Asset Management, Tourbillon Capital Partners and...

  • Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...

  • Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, sending its shares up 9.4 percent in premarket trading. An earlier application was rejected by the FDA in February 2013. Dynavax's shares closed at $21.18 on the Nasdaq on Wednesday.

  • Jan 7- Dutch biotech UniQure NV said on Thursday its experimental gene therapy for a blood disorder benefited some patients in an early-stage study, sending its shares up about 20 percent in light premarket trading. UniQure said after being treated with the drug, four out of five patients were able to fully discontinue taking prophylactic rFIX, which is...

  • Jan 7- Dutch biotech UniQure NV said its experimental gene therapy for a blood clotting disorder benefited some patients in an early-stage study.

  • Dec 20- Martin Shkreli, the pharmaceutical executive facing U.S. charges of securities fraud, lost control of his Twitter account to hackers on Sunday, hours after he took to Twitter to plead his innocence, his spokesman said. "It was hacked," Craig Stevens, a spokesman for the former chief executive of Turing Pharmaceuticals, said in an email. "We have been working with...

  • Dec 18- Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday. Shkreli has been under investigation for securities fraud related to hedge fund MSMB Capital Management and...

  • Dec 18- Privately held drugmaker Turing Pharmaceuticals Inc is close to replacing Chief Executive Martin Shkreli, the Wall Street Journal reported on Friday, a day after the FBI arrested him on charges of securities fraud. Shkreli was charged in a federal indictment on Thursday related to his time managing hedge fund MSMB Capital Management and CEO of...

  • Dec 18- Privately held drugmaker Turing Pharmaceuticals Inc is close to replacing Chief Executive Martin Shkreli, the Wall street Journal reported on Friday, a day after the FBI arrested him on charges of securities fraud. Shkreli was charged in a federal indictment on Thursday related to his time managing hedge fund MSMB Capital Management and CEO of...